Cardiome Pharma (CRME) Misses Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Cardiome Pharma (CRME) Misses Q2 EPS by 18c
August 9, 2016 4:00 PM EDT
Cardiome to conduct conference call and webcast today, August 9, 2016 at 4:30pm Eastern (1:30pm Pacific)
NASDAQ: CRMEÂ Â Â Â TSX: COM
VANCOUVER, Aug. 9, 2016 /PRNewswire/ -Â Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for its second quarter ended June 30, 2016. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP).
Commenting on Cardiome's Q2, Dr. William Hunter, CEO, said "We believe that the 16% year-over-year... More
August 9, 2016 4:00 PM EDT
NASDAQ: CRMEÂ Â TSX: COM
VANCOUVER, Aug. 9, 2016 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced that XYDALBA (dalbavancin) has been approved by the European Medicines Agency (EMA) for administration as a single, 30 minute, 1500mg infusion (three 500mg vials). This single dosing regimen is in addition to the initially approved dosing regimen of 1000 mg (two 500mg vials) followed one week later by 500 mg (a single 500mg vial).
"We are pleased that the EMA has approved the single dose administration of XYDALBA," said Kiran Bhirangi, M.D., Cardiome's... More
